Seletracetam
From Wikipedia, the free encyclopedia
Seletracetam
|
|
Systematic (IUPAC) name | |
(2S)-2-[(4R)-4-(2,2-difluoroethenyl) -2-oxo-pyrrolidin-1-yl]butanamide | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C10H14F2N2O |
Mol. mass | 232.227 |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | >90% |
Metabolism | ? |
Half life | 8h |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
Unscheduled (US) |
Routes | Oral |
Seletracetam is a drug of the racetam family. It is currently being developed by UCB Pharmaceuticals as an anticonvulsant drug. While similar in structure to so-called nootropic drugs, it is not expected to have cognitive enhancing properties.
[edit] See also
|